Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 6Phase 1/2 3Phase NA 2Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Neoplasm Metastasis 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × WW Domain-Containing Oxidoreductase × Clear all
NCT02412878 2022-09-23

ARROW

Amgen

Phase 3 Completed
478 enrolled 17 charts
Plasma cell

Multiple Myeloma

NCT00083993 2011-11-08

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Terminated
1,236 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡